These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 25517746

  • 21. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
    Long G.
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
    [No Abstract] [Full Text] [Related]

  • 22. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
    Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS.
    Cancer Cell; 2015 Feb 09; 27(2):240-56. PubMed ID: 25600339
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. BRAF signaling and targeted therapies in melanoma.
    Dhomen N, Marais R.
    Hematol Oncol Clin North Am; 2009 Jun 09; 23(3):529-45, ix. PubMed ID: 19464601
    [Abstract] [Full Text] [Related]

  • 29. Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis.
    Kim S, Kim HT, Suh HS.
    J Dermatolog Treat; 2018 May 09; 29(3):314-321. PubMed ID: 28504036
    [Abstract] [Full Text] [Related]

  • 30. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 31. Protein kinase inhibitors in melanoma.
    Eigentler TK, Meier F, Garbe C.
    Expert Opin Pharmacother; 2013 Nov 01; 14(16):2195-201. PubMed ID: 23992377
    [Abstract] [Full Text] [Related]

  • 32. The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?
    Nissan MH, Solit DB.
    Curr Oncol Rep; 2011 Dec 01; 13(6):479-87. PubMed ID: 21997758
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Novel Targeted Therapies for Metastatic Melanoma.
    Iams WT, Sosman JA, Chandra S.
    Cancer J; 2017 Dec 01; 23(1):54-58. PubMed ID: 28114255
    [Abstract] [Full Text] [Related]

  • 38. Development of encorafenib for BRAF-mutated advanced melanoma.
    Koelblinger P, Thuerigen O, Dummer R.
    Curr Opin Oncol; 2018 Mar 01; 30(2):125-133. PubMed ID: 29356698
    [Abstract] [Full Text] [Related]

  • 39. MEK inhibition in the treatment of advanced melanoma.
    Salama AK, Kim KB.
    Curr Oncol Rep; 2013 Oct 01; 15(5):473-82. PubMed ID: 23975010
    [Abstract] [Full Text] [Related]

  • 40. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.
    Jung T, Haist M, Kuske M, Grabbe S, Bros M.
    Int J Mol Sci; 2021 Sep 13; 22(18):. PubMed ID: 34576054
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.